No Data
No Data
Hehuang Pharmaceutical (00013.HK): Initiating a RAPHAEL registered phase III study on HMPL-306 in the treatment of relapsed/refractory acute myeloid leukemia patients with IDH1 and/or IDH2 mutations in China
On May 14, Ge Longhui Pharmaceutical (00013.HK) announced today the launch of a registered phase clinical trial of HMPL-306 to treat relapsed/refractory acute myeloid leukemia (AML) with isocitrate dehydrogenase (“IDH”) 1 or 2 mutations in China. The first test subject received the first dose of medication on May 11, 2024.
Hehuang Pharmaceutical (00013.HK) and Hengrui Pharmaceutical reached a cooperation and initiated a phase II/III study on surufatinib (surufatinib) combined with camrelizumab (camrelizumab) in the treatment of primary pancreatic ductal adenocarcinoma
Gelonghui, May 14, 丨 Hehuang Pharmaceutical (00013.HK) announced the launch of a Chinese phase II/III clinical trial today to evaluate Hehuang Pharmaceutical's drug candidate surufatinib (surufatinib), the PD-1 antibody camrelizumab (camrelizumab) of Jiangsu Hengrui Pharmaceutical Co., Ltd. (“Hengrui Pharmaceutical”), albumin-conjugated paclitaxel (nab-paclitaxel), and gemcitabine (gemcitabine) for first-line treatment of metastatic pancreatic conduction Ductal adenocarcinoma (PDAC) patients
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma in Collaboration With Hengrui
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces the initiation of a Phase II/III trial to evaluate the efficacy of a combination of the HUTCHMED drug candidate surufatinib, the Jiangsu Hengrui Pharmaceuticals Co., Ltd PD-1 antibody camrelizumab, nab-paclitaxel and gemcitabine as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma ("PDAC") in China.
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients With IDH1- And/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-306 in patients with mutated isocitrate dehydrogenase ("IDH") 1 or 2 relapsed / refractory acute myeloid leukemia ("AML") in China. The first patient received their first dose on May 11, 2024.
6-K: Report of foreign private issuer (related to financial reporting)
Spectrum Brands Posts Upbeat Results, Joins AerSale, Sinclair, ICU Medical And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones gaining around 100 points on Thursday.Shares of Spectrum Brands Holdings, Inc. (NYSE:SPB) rose sharply during Thursday's session following upbeat earnings.Sp